Blepharitis Treatment is Estimated to Witness High Growth Owing to Easy Accessibility of Products

Blepharitis is a common problem of eyelids characterized by inflammation and scaling of eyelid margin which can cause red, irritated eyes. Blepharitis treatment includes artificial tears, warm compresses, lid scrubs and oral antibiotics to reduce redness and flaking of eyelids. The easy accessibility of blepharitis treatment products like eyelid scrubs, cleansers, warm compresses and wipes through various distribution channels including pharmacies, hypermarkets and e-commerce sites have helped in increasing awareness and adoption of blepharitis treatment among patients suffering from this eye problem. The global Blepharitis Treatment Market is estimated to be valued at US$ 2.5 Bn in 2023 and is expected to exhibit a CAGR of 10% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Opportunity

Easy accessibility of blepharitis treatment products is estimated to boost market growth significantly during the forecast period. Various blepharitis treatment products like scrubs, wipes, cleansers and compress pads are easily available through both offline and online distribution channels. This wide availability of products have helped patients in self-diagnosing their condition and providing temporary relief. Moreover, the rising popularity of e-commerce platforms along with convenience of online shopping have further increased accessibility of these products to both urban and rural areas globally. The easy accessibility of effective blepharitis treatment products through multiple sales channels is expected to present lucrative growth opportunities for players in the global blepharitis treatment market during the forecast period.

Porter’s Analysis
Threat of new entrants: The blepharitis treatment market has moderate threat of new entrants due to availability of established branded drugs and high R&D cost required for new drug development. However, scope exists for new generic players.
Bargaining power of buyers: The bargaining power of buyers is moderate due to availability of established treatment options. However, increasing awareness about blepharitis treatment increases buyers’ power.
Bargaining power of suppliers: Established suppliers like drug makers have significant power given proprietary technologies and expertise required.
Threat of new substitutes: Threat of substitutes is low as blepharitis has limited treatment options currently.
Competitive rivalry: Market dominated by few global established players.

SWOT Analysis
Strength: Rapidly growing market size. Established distribution channels.
Weakness: Need for continuous innovation. High R&D costs.
Opportunity: Increasing blepharitis disease prevalence. Emerging Asian markets growth.
Threats: Price erosion due to competition.supply chain and production disruptions.

Key Takeaways
The global blepharitis treatment market is expected to witness high growth at a CAGR of 10% during the forecast period of 2023 to 2030. The market size for blepharitis treatment in 2024 is estimated to reach US$ 2.5 Bn.

Regional analysis – North America dominates currently owing to robust healthcare systems and awareness. Asia Pacific expected to grow fastest during the forecast period due to rising incomes, healthcare reforms and patents expiration of major drugs.

Key players operating in the blepharitis treatment market are Scope Ophthalmic Ltd., NovaBay Pharmaceuticals Inc., Thea Pharmaceuticals Ltd., Perrigo Laboratories, InSite Vision Incorporated, Merck & Co., and Novartis AG. Scope Ophthalmic Ltd. holds a significant share in the market. Recent collaboration between Scope Ophthalmic Ltd. and Johnson and Johnson is expected to further strengthen Scope’s market position.